Axsome Therapeutics, Inc.AXSMNASDAQ
LOADING
|||
Switch Symbol:
AXSM Revenue Growth (YoY Quarterly)•+63.22%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +81.27% | +66.04% | +61.95% | +72.13% | +63.22% |
| Gross Profit Growth | +87.91% | +68.74% | +62.55% | +72.66% | +65.15% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.17% | +2.56% | +3.12% | +3.93% | +3.91% |
| Weighted Average Shares Diluted Growth | +2.17% | +2.56% | +3.12% | +3.93% | +3.91% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +58.26% | +49.76% | +59.12% | +65.22% | +58.35% |
| Inventory Growth | +42.86% | +3.94% | +4.72% | +21.16% | +66.66% |
| Asset Growth | -6.56% | -3.36% | +9.33% | +16.70% | +19.20% |
| Book Value per Share Growth | -66.26% | -70.89% | -64.18% | -31.64% | -23.62% |
| Debt Growth | +3.62% | +3.53% | +11.51% | +13.30% | +13.67% |
| R&D Expense Growth | +57.78% | +78.57% | +21.60% | -0.63% | -11.51% |
| SG&A Expenses Growth | +14.88% | +30.48% | +22.04% | +25.81% | +57.21% |
1 / 4